HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Dingdang Health Technology (9886HK)-Business Model Face Test; Hard to Run the Ecosystem Successfully

Ping An Healthcare and Technology (1833.HK) - The New Acquisition Is Hard to Turn Things Around

Pre-IPO MedSci Healthcare Holdings - The Investment Logic, the Business Analysis and the Risks

Alibaba Health Information Technology (241.HK) - It’s Not Easy to Break a Deadlock

Ping An Healthcare and Technology (1833.HK) - Untenable Business Model Worsen the Logic and Outlook

JD Health (6618.HK) - Logic Change Due to the New Policy?

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

JD Health International  / Equity Bottom-Up

<ul>
<li>JD Health bucked the trend and grew in 2022H1. The Company has turned a profit first in front of its competitors Alibaba Health and Ping An Good Doctor.</li>
<li>The performance of the second growth point would determine whether JD Health can maintain good momentum under the challenges of policy risks and possible future bottlenecks of products revenue growth. </li>
<li>Hopefully, the smart healthcare solutions and digital health business or the pet healthcare business can achieve breakthroughs. Then, there’re more certainty in long-term performance and valuation growth of JD Health.</li>
</ul>


JD Health bucked the trend and grew in 2022H1. The Company has turned a profit first in front of its competitors Alibaba Health and Ping An Good Doctor.
The performance of the second growth point would determine whether JD Health can maintain good momentum under the challenges of policy risks and possible future bottlenecks of products revenue growth. 
Hopefully, the smart healthcare solutions and digital health business or the pet healthcare business can achieve breakthroughs. Then, there’re more certainty in long-term performance and valuation growth of JD Health.


Ping An Healthcare and Technology (1833 HK)

JD Health (6618.HK) 2022H1 - A Second Growth Point Is Needed to Reassure Investment Logic